drugset / Trial / NCT02892019

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

NCT02892019

Phase 2 Completed 79 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to explore lung function effects of two doses of indacaterol acetate, 75 μg and 150 μg, in pediatric asthma patients 6-11 years old, and to compare the systemic exposure to indacaterol in plasma with historical data in adults, to identify an appropriate dose to Phase III evaluation.

Timeline

Start
2017-04-18
Primary completion
2019-06-19
Completion
2019-07-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Indacaterol Other / unclassified 75 ug Inhaled
Comparator Indacaterol Other / unclassified 150 ug Inhaled

Indications